CD19 and cancer: The level of targeted CD19 determines the efficacy of anti-CD19 CAR T cell therapy of B cell malignancies as pointed out by Michael C. Jensen (Seattle Children's Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA, USA).